Chile's Institute of Public Health issues an information notice on the safety of Pfizer-BioNTech's COVID-19 vaccine following reports of myocarditis and pericarditis
On 23 September 2021, Chile's Public Health Institute (ISP) issued an information notice on the safety of the PfizerBioNTech COVID-19 vaccine, after cases of myocarditis and pericarditis following administration of the vaccine were reported. The ISP notes that, in Chile, since 16 December 2020, more than 6.8 million doses of this vaccine have been administered, and it has received a total of 11 reports of myocarditis and/or pericarditis, of which 10 were serious cases. Of the total reported cases, seven occurred in men and four in women; the mean age was 22 years, with median age of 19 years (14–32 years). These cases are being evaluated by Chile's Committee of Experts on Vaccine
Pharmacovigilance, which concluded that four of the cases are “consistent with vaccination.”
In this information notice, directed at the community, the ISP indicated that, after administration of the Pfizer-BioNTech COVID-19 vaccine, there is a very low probability that myocarditis and/or pericarditis will occur, mostly in young men after the second dose, in the 14 days after vaccination. The ISP alerts people to the need to seek medical attention immediately if, in the days following vaccination, they experience shortness of breath, heart palpitations sometimes accompanied by an irregular heartbeat, feel faint, or have chest pain.
The ISP also notes that the benefit of the Pfizer-BioNTech COVID-19 vaccine in preventing COVID-19 hospitalizations and deaths outweighs the risks described.